EORTC Radiation Oncology Group: 50 years of continuous accomplishments

European Journal of Cancer, Supplement

Volumn 10, Issue 1, 2012, Pages 150-159

  Grégoire, Vincent ^a   Bartelink, Harry ^b   Bernier, Jacques ^c   Bolla, Michel ^d   Bosset, Jean François ^e   Collette, Laurence ^f   Haustermans, Karin ^g   Horiot, Jean Claude ^c   Hurkmans, Coen W ^h   Mirimanoff, René ⁱ   Poortmans, Philip ^j   Weber, Damien C ^k   Maingon, Philippe ^l  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Genolier Swiss Medical Network SA   (Switzerland)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^f EORTC DATA CENTER   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CATHARINA HOSPITAL   (Netherlands)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j Institute Verbeeten   (Netherlands)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^l CENTRE GEORGES FRANÇOIS LECLERC   (France)

more..

Author keywords

Brain; Breast; Head and neck; IMRT; Prostate; QA RT; Radiotherapy; Rectum

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GONADORELIN AGONIST; MITOMYCIN C; TEMOZOLOMIDE;

ADD ON THERAPY; ANDROGEN DEPRIVATION THERAPY; ANUS CANCER; ANUS TUMOR; ARTICLE; BRAIN TUMOR; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL STUDY; DRUG MEGADOSE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL LITERATURE; NONHODGKIN LYMPHOMA; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PUBLICATION; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM TUMOR;

EID: 84858251248     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/S1359-6349(12)70024-1     Document Type: Article

References (52)

1. Haie C, Pejovic MH, Gerbaulet A, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 1988, 11(2):101-112.
2. Ang KK, van der Schueren E, Notter G, et al. Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas. A pilot feasibility study of the Radiotherapy Group of the EORTC. Int J Radiat Oncol Biol Phys 1982, 8(10):1657-1664.
3. Van den Bogaert W, van der Schueren E, Van Tongelen C, et al. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group. Radiother Oncol 1985, 3(2):139-144.
4. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992, 326(8):524-530.
5. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15(5):2040-2049.
6. van den Bent MJ, Afra D, de Witte O, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366(9490):985-990.
7. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996, 36(3):549-556.
8. González DG, Menten J, Bosch DA, et al. Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study. Radiother Oncol 1994, 32(2):98-105.
9. Miralbell R, Mornex F, Greiner R, et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999, 17(10):3143-3149.
10. Stupp R, Mason WP, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
11. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20(5):1375-1382.
12. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
13. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006, 24(16):2563-2569.
14. Stupp R, Hegi ME, Mason WP, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466.
15. Brandes AA, Stupp R, Hau P, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010, 46(2):348-354.
16. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25(4):231-241.
17. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997, 44(2):111-121.
18. Bernier J, Domenge C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350(19):1945-1952.
19. Lefebvre JL, Rolland F, Tesselaar M, EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009, 101(3):142-152.
20. van Dongen JA, Bartelink H, Fentiman IS, et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. Eur J Cancer 1992, 28A(4-5):801-805.
21. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387.
22. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25(22):3259-3265.
23. Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC trial 22881-10882 "boost versus no boost" Eur J Cancer 2008, 44:2587-2599.
24. Van Werkhoven E, Hart G, van Tinteren H, et al. Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. Radiother Oncol 2011, 100:101-107.
25. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
26. Bolla M, Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study); a phase III randomized trial. Lancet 2002, 360:103-108.
27. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk. 10-year results of an EORTC randomized study. Lancet Oncol 2010, 11:1066-1073.
28. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
29. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled rtrial (EORTC trial 22911). Lancet 2005, 366:572-578.
30. Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007, 84:121-127.
31. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet 1996, 348(9034):1049-1054.
32. Bosset JF, Roelofsen F, Morgan DA, European Organization for Research and Treatment of Cancer, et al. Radiotherapy and Gastrointestinal Cooperative Groups. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003, 39(1):45-51.
33. Matzinger O, Roelofsen F, Mineur L, EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009, 45(16):2782-2791.
34. Bosset JF, Pavy JJ, Hamers HP, et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D, L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. Eur J Cancer 1993, 29A(10):1406-1410.
35. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol 2005, 23(24):5620-5627.
36. Bosset JF, Collette L, Calais G, EORTC Radiotherapy Group Trial 22921, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-1123.
37. Collette L, Bosset JF, den Dulk M, European Organisation for Research and Treatment of Cancer Radiation Oncology Group, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25(28):4379-4386.
38. den Dulk M, Putter H, Collette L, et al. The abdomino-perineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer 2009, 45(7):1175-1183.
39. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011, 29(23):3163-3172.
40. Horiot JC, Johansson KA, Gonzalez DG, van der Schueren E, van den Bogaert W, Notter G Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organization for Research and Treatment of Cancer. Radiother Oncol 1986, 6(4):275-284.
41. Johansson KA, Horiot JC, Van Dam J, Lepinoy D, Sentenac I, Sernbo G Quality assurance control in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison. Radiother Oncol 1986, 7(3):269-279.
42. Johansson KA, Horiot JC, van der Schueren E Quality assurance control in the EORTC cooperative group of radiotherapy. 3. Intercomparison in an anatomical phantom. Radiother Oncol 1987, 9(4):289-298.
43. Horiot JC, van der Schueren E, Johansson KA, Bernier J, Bartelink H The programme of quality assurance of the EORTC radiotherapy group. A historical overview. Radiother Oncol 1993, 29(2):81-84.
44. Fairchild A, Gulyban A, Denis J International IMRT credentialing by physical phantom iradiation: The EORTC ROG experience. Radiother Oncol 2011, 99. abstr 392.
45. Kouloulias VE, Poortmans PM, Bernier J, et al. The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): a critical appraisal of 20 years of continuous efforts. Eur J Cancer 2003, 39(4):430-437.
46. Budiharto T, Musat E, Poortmans P, EORTC Radiation Oncology Group, et al. Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother Oncol 2008, 88(3):403-410.
47. Bolla M, Bartelink H, Garavaglia G, et al. EORTC guidelines for writing protocols for clinical trials of radiotherapy. Radiother Oncol 1995, 36(1):1-8.
48. Matzinger O, Poortmans P, Giraud JY, EORTC Radiation Oncology Group, et al. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. Radiother Oncol 2009, 90(3):285-290.
49. Musat E, Poortmans P, Van den Bogaert W, et al. Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer 2007, 43(4):718-724.
50. Valley JF, Bernier J, Tercier PA, et al. Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run. Radiother Oncol 1998, 47(1):37-44.
51. van Tienhoven G, Mijnheer BJ, Bartelink H, González DG Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview. Strahlenther Onkol 1997, 173(4):201-207.
52. Weber DC, Poortmans PM, Hurkmans CW, Aird E, Gulyban A, Fairchild A Quality assurance for prospective EORTC radiation oncology trials: The challenges of advanced technology in a multicenter international setting. Radiother Oncol 2011, 100:150-156.